SCHEMBL20148917

SCHEMBL20148917

NC(=O)c1n[nH]c(-c2nc(Cc3ccccc3F)c3ccccn23)n1

nearest known ligand 0.40

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
AR P10275 1/20 0.40
GUCY1A1 Q02108 6/20 0.37
GUCY1B1 Q02153 6/20 0.37
KCNH2 Q12809 2/20 0.37
ALDH1A1 P00352 3/20 0.36
HIF1A Q16665 1/20 0.35
EPAS1 Q99814 1/20 0.35
KDM4E B2RXH2 2/20 0.34
MEN1 O00255 1/20 0.34
KMT2A Q03164 1/20 0.34
RXFP1 Q9HBX9 1/20 0.34
LMNA P02545 1/20 0.33
MPO P05164 1/20 0.33
PDE5A O76074 1/20 0.33
PTGDR2 Q9Y5Y4 1/20 0.32
RIPK1 Q13546 1/20 0.32
PLK1 P53350 1/20 0.32
TP53 P04637 1/20 0.32
MAPT P10636 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23510580 0.84 AR (0.31) ARGUCY1A1GUCY1B1KCNH2
SCHEMBL20148879 0.83 AR (0.41) ARGUCY1A1GUCY1B1KCNH2ALDH1A1
SCHEMBL21564207 0.80 AR (0.39) ARGUCY1A1GUCY1B1KCNH2ALDH1A1
SCHEMBL20148877 0.80 AR (0.39) ARGUCY1A1GUCY1B1KCNH2ALDH1A1
SCHEMBL20148902 0.80 HIF1A (0.43) ARGUCY1A1GUCY1B1KCNH2ALDH1A1
SCHEMBL20148918 0.80 AR (0.40) ARGUCY1A1GUCY1B1KCNH2ALDH1A1
SCHEMBL21564211 0.78 AR (0.38) ARGUCY1A1GUCY1B1KCNH2ALDH1A1
SCHEMBL20148878 0.76 PIM1 (0.43) ARGUCY1A1GUCY1B1KCNH2ALDH1A1
SCHEMBL29757105 0.72 RIPK1 (0.49) ARALDH1A1KDM4EMEN1KMT2A
SCHEMBL21787231 0.71 AR (0.36) ARGUCY1A1GUCY1B1ALDH1A1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3538096-B1 TREATMENT OF CNS DISEASES WITH SGC STIMULATORS TISENTO THERAPEUTICS INC (US) 2024-02-28 EP disclosed
US-20230381153-A1 TREATMENT OF CNS DISEASES WITH sGC STIMULATORS TISENTO THERAPEUTICS INC. 2023-11-30 US disclosed
US-20230381153-A1 TREATMENT OF CNS DISEASES WITH sGC STIMULATORS TISENTO THERAPEUTICS INC. 2023-11-30 US disclosed
US-11690828-B2 Treatment of CNS diseases with sGC stimulators CYCLERION THERAPEUTICS, INC. (US) 2023-07-04 US disclosed
US-11690828-B2 Treatment of CNS diseases with sGC stimulators CYCLERION THERAPEUTICS, INC. (US) 2023-07-04 US disclosed
US-20190343813-A1 TREATMENT OF CNS DISEASES WITH sGC STIMULATORS CYCLERION THERAPEUTICS, INC. (US) 2019-11-14 US disclosed
WO-2018111795-A2 USE OF SGC STIMULATORS FOR THE TREATMENT OF ESOPHAGEAL MOTILITY DISORDERS IRONWOOD PHARMACEUTICALS, INC. (US) 2018-06-21 WO disclosed
WO-2018089328-A1 TREATMENT OF CNS DISEASES WITH SGC STIMULATORS IRONWOOD PHARMACEUTICALS, INC. (US) 2018-05-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190343813-A1 TREATMENT OF CNS DISEASES WITH sGC STIMULATORS GUCY1A2, GUCY1B2, PDE2A AR 4768/4885GUCY1A1 4/4885GUCY1B1 5/4885
US-11690828-B2 Treatment of CNS diseases with sGC stimulators GUCY1A2, GUCY1B2, PDE2A AR 4768/4885GUCY1A1 4/4885GUCY1B1 5/4885
US-20230381153-A1 TREATMENT OF CNS DISEASES WITH sGC STIMULATORS GUCY1A2, GUCY1B2, PDE2A AR 4768/4885GUCY1A1 4/4885GUCY1B1 5/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.